Faisal Qureshi

TL;DR: A 69-year-old Caucasian male with type 2 diabetes suffering from non-small cell lung cancer and undergoing treatment with pembrolizumab, an anti-programmed cell death protein-1 antibody is presented, found to have high anion gap metabolic acidosis with ketosis and elevated blood glucose levels consistent with DKA.

TL;DR: In this paper, a review of strategies associated with hypoglycemia risk reduction among critically ill non-pregnant adult patients is presented, where caregivers should define responses to interruption of continuous carbohydrate exposure, incorporate transitioning strategies upon initiation and interruption of IV insulin, define modifications of antihyperglycemic therapy in the presence of worsening renal function or chronic kidney disease.

TL;DR: The case of a patient with type 2 diabetes who presented with euglycemic DKA within 2 months of starting canagliflozin/metformin therapy, and had severe hypophosphatemia with phosphate levels <1 mg/dL during the recovery phase, requiring repletion of phosphate.

TL;DR: It is hypothesize that a strictly increasing sigmoidal relationship between MR-dependent IR and BG may reduce risk for hypoglycemia, in comparison to a linear relationship between multiplier-dependentIR and BG.

TL;DR: A case of hypophysitis resolving with corticosteroid treatment, following which the patient developed long-term primary thyroid impairment, highlights the importance of vigilance for rarer immune-related toxicities as clinical utilization of ipilimumab becomes more widespread.